TABLE 4.
Susceptibility of HCMV laboratory strains and clinical isolates to AIC246 and GCV
| HCMV strain | EC50a (μM) |
|
|---|---|---|
| AIC246 | Ganciclovir | |
| Laboratory strains | ||
| AD169 | 0.0051 ± 0.0012 | 2.4 ± 2.5 |
| AD169 rGCVb | 0.0039 ± 0.0011 | 12 ± 0.7 |
| Clinical isolates | ||
| I-Se | 0.0031 ± 0.0038 | NDc |
| I-Ba | 0.0058 ± 0.0001 | ND |
| I-La | 0.0034 ± 0.0035 | ND |
| I-472 | 0.0018 ± 0.0016 | 5.0 ± 3.90 |
| I-E16415Sd | 0.0026 ± 0.0016 | 1.1 ± 0.45 |
| GCV-resistant clinical isolates | ||
| I-E17251Sd,e | 0.0061 ± 0.0044 | 14 ± 2.5 |
| I-1947Rd,e | 0.0023 ± 0.0023 | 15 ± 13 |
a
EC50values were determined by the CPE reduction assay as described in Materials and Methods. Data are means of at least two independent experiments and are expressed ± standard deviations.
b
GCV-resistant AD169 virus (UL97 M460I).
c
ND, not determined.
d
Cell-associated viruses (virus-infected cells) were used as viral inocula.
e
GCV-resistant clinical isolate (UL97 C603W).